Notably, IL-17-associated elevation of TH17 cells, dendritic cells and neutrophils is already present in untreated tumors (TCGA-SKCM data), suggesting that subgroups of melanomas harbor a pre-existent immune composition that may determine susceptibility to dual ICI upfront to therapy. The gene discussed is IL17A; the disease is melanoma.